This article is more than 5 years old. Information may no longer be current.

Case reports: COX-2 inhibitors associated retinal vein occlusions

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Patients predisposed to thrombosis may be at risk for cardiovascular or ocular thrombotic events when taking a COX-2 inhibitor, a case series suggests.

Carsten H. Meyer and colleagues at Philipps University in Germany described the cases of three patients with sudden decreases in vision. All three were prescribed rofecoxib, the COX-2 inhibitor marketed as Vioxx. One female patient had rheumatoid arthritis, one had severe osteoporosis and a male patient had hip pain. The mean age of the women was 70, and the man was 47.

In each cases, after taking Vioxx for a short period, the patient developed central retinal vein occlusion or branch retinal vein occlusion.

The study is published in Ophthalmologica.